Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPERFUSE: Vasopressor Therapy on Renal Perfusion in Septic Shock
NCT06234592Recruiting
- Sponsor
- King's College Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of Angiotensin II and vasopressin in septic shock (3 arms), sponsored by King's College Hospital. Primary endpoint: Cortical mean transit time at 24 hours. Started Jan 2024; status: recruiting.
02
Drugs
Angiotensin IIvasopressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT06234592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234592.